Selective expansion of T-cell receptor engineered T cells with increased stem-like phenotypes using neoantigen stimulation
These findings demonstrate that NeoExpand enables selective expansion of TCR-T cells while preserving favorable phenotypes and scalability. The approach supports further clinical evaluation of NeoExpand as a strategy to generate high-quality TCR-T cell products for adoptive cell therapy.
Authors
- Noam Levin (ORCID: https://orcid.org/0000-0003-0664-2808)
- Satyajit Ray (ORCID: https://orcid.org/0000-0002-3260-5982)
- You Hwan Jo (ORCID: https://orcid.org/0000-0002-9507-7603)
- Nolan R. Vale (ORCID: https://orcid.org/0000-0002-7422-4918)
- Melinda Magna
- Nicholas D. Klemen (ORCID: https://orcid.org/0000-0003-1353-539X)
- Zhiya Yu (ORCID: https://orcid.org/0000-0003-3742-5902)
- Sanghyun P. Kim (ORCID: https://orcid.org/0000-0001-9519-1994)
- L Lévy (ORCID: https://orcid.org/0000-0002-2727-025X)
- Steven A. Rosenberg (ORCID: https://orcid.org/0000-0002-8939-8910)
- Mamduh Khateb (ORCID: https://orcid.org/0000-0002-6347-3361)
- Stephanie L. Goff (ORCID: https://orcid.org/0000-0003-3317-9804)
- Shahram S. Farid
- Hyunmi Halas (ORCID: https://orcid.org/0009-0007-3933-6459)
- Maria Parkhust
- Charles Marquardt
Institutions
- National Cancer Institute (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1136/jitc-2025-013373
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca
- National Institutes of Health
- National Cancer Institute